Armata Pharmaceuticals, Inc.
ARMP- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000921114
No open-market purchases or sales by Armata Pharmaceuticals, Inc. insiders were filed in the last 90 days; 53 institutions reported holding it in 13F filings for Q2 2026, worth $32.3M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 13, 2026, 1:15 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 25, 2026 | Mar 21, 2025 | Mar 21, 2024 | Mar 16, 2023 | – |
| Operating expenses | $41.5M | $47.6M | $45.4M | $42.5M | $28.3M |
| Research and development | $23.7M | $34.4M | $33.8M | $35.0M | $20.0M |
| Selling, general and administrative | $12.4M | $13.2M | $11.6M | $7.44M | $8.28M |
| Operating income | -$36.6M | -$42.4M | -$40.9M | -$36.9M | -$23.8M |
| Interest expense | – | – | $2.63M | $0 | $64.0K |
| Net income | -$173.8M | -$18.9M | -$69.0M | -$36.9M | -$23.2M |
| EPS, basic | $-4.80 | $-0.52 | $-1.91 | $-1.08 | $-0.96 |
| EPS, diluted | $-4.80 | $-0.89 | $-1.91 | $-1.08 | $-0.96 |
| Weighted shares, basic | 36.2M | 36.2M | 36.1M | 34.3M | 24.1M |
| Weighted shares, diluted | 36.2M | 59.1M | 36.1M | 34.3M | 24.1M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 25, 2026 | Mar 21, 2025 | Mar 21, 2024 | Mar 16, 2023 | – |
| Cash and equivalents | $8.69M | $9.29M | $13.5M | $14.9M | $10.3M |
| Total current assets | $10.7M | $11.3M | $19.2M | $27.0M | $15.0M |
| Property, plant and equipment | $12.2M | $13.2M | $12.6M | $3.62M | $2.22M |
| Goodwill | $3.49M | $3.49M | $3.49M | $3.49M | $3.49M |
| Intangible assets | $10.3M | $10.3M | $10.3M | $10.3M | $10.3M |
| Total assets | $76.9M | $86.4M | $98.4M | $95.8M | $69.8M |
| Accounts payable | $921.0K | $766.0K | $1.58M | $1.68M | $1.14M |
| Total current liabilities | $8.95M | $48.2M | $16.5M | $24.9M | $4.81M |
| Total liabilities | $295.5M | $134.5M | $130.4M | $59.8M | $44.4M |
| Shareholders' equity | -$218.6M | -$48.0M | -$32.1M | $36.1M | $25.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 25, 2026 | Mar 21, 2025 | Mar 21, 2024 | Mar 16, 2023 | – |
| Operating cash flow | -$25.8M | -$37.6M | -$47.4M | -$32.5M | -$23.6M |
| Capital expenditures | $542.0K | $1.88M | $8.14M | $2.21M | $1.30M |
| Free cash flow | -$26.3M | -$39.4M | -$55.6M | -$34.7M | -$24.9M |
| Depreciation and amortization | – | $1.32M | $972.0K | – | – |
| Stock-based compensation | $2.61M | $2.89M | $938.0K | $3.10M | $2.88M |
| Investing cash flow | -$542.0K | -$1.88M | -$8.13M | -$2.21M | -$1.30M |
| Financing cash flow | $25.6M | $35.0M | $54.0M | $44.0M | $25.5M |
| Net change in cash | -$693.0K | -$4.47M | -$1.57M | $9.32M | $639.0K |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 6, 2026 | 37.2M | +2.4% | SEC |
| Aug 6, 2026 | 37.2M | +2.6% | SEC |
| May 8, 2026 | 36.7K | −99.9% | SEC |
| Mar 18, 2026 | 36.6M | +1.2% | SEC |
| Nov 4, 2025 | 36.3M | +0.4% | SEC |
| Aug 6, 2025 | 36.2M | +0.1% | SEC |
| May 8, 2025 | 36.2M | +0.1% | SEC |
| Feb 28, 2025 | 36.2M | +0.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.